Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam-Reference-Cited by-同舟云学术

Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam

Published:2017-08 Issue:8 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zhang Yunliang¹,Kashikar Ankita¹,Brown C. Adam¹,Denys Gerald²,Bush Karen¹^ORCID

Affiliation:

1. Indiana University, Bloomington, Indiana, USA

2. Indiana University School of Medicine, Indianapolis, Indiana, USA

Abstract

ABSTRACT Carbapenemase-producing Enterobacteriaceae isolates ( n = 110) from health care centers in central Indiana (from 2010 to 2013) were tested for susceptibility to combinations of avibactam (4 μg/ml) with ceftazidime, ceftaroline, or aztreonam. MIC 50 /MIC 90 values were 1/2 μg/ml (ceftazidime-avibactam), 0.5/2 μg/ml (ceftaroline-avibactam), and 0.25/0.5 μg/ml (aztreonam-avibactam.) A β-lactam MIC of 8 μg/ml was reported for the three combinations against one Escherichia coli isolate with an unusual TIPY insertion following Tyr344 in penicillin-binding protein 3 (PBP 3) as the result of gene duplication.

Funder

Allergan, Plc

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00389-17

Reference24 articles.

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention,Atlanta, GA.

2. World Health Organization. 2014. Antimicrobial resistance: global report on surveillance 2014. World Health Organization,Geneva, Switzerland.

3. Carbapenemase-Producing Enterobacteriaceae

4. Treatment options for infections caused by carbapenem-resistantEnterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?

5. In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mediastinitis caused by an NDM-1 Escherichia coli in a child with Dacron Sano shunt after pulmonary atresia with ventricular septal defect surgery treated with combination of aztreonam-avibactam;International Journal of Antimicrobial Agents;2024-10

2. Emergence of high-level aztreonam–avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline;JAC-Antimicrobial Resistance;2024-09-03

3. MultiRapid ATB NP test for detecting concomitant susceptibility and resistance of last-resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections;International Journal of Antimicrobial Agents;2024-08

4. Genomic characterization of carbapenemase-producing Enterobacterales from Dhaka food markets unveils the spread of high-risk antimicrobial-resistant clones and plasmids co-carrying blaNDM and mcr-1.1;JAC-Antimicrobial Resistance;2024-07-03

5. The Triple Combination of Meropenem, Avibactam, and a Metallo-β-Lactamase Inhibitor Optimizes Antibacterial Coverage Against Different β-Lactamase Producers;Engineering;2024-07